Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb

 April 9, 2026

PharmaTimes

Partnership to develop nextgeneration Tcell engagers for solid tumours

M&A / DealsRead full story

Post navigation

Innovent’s CDMO gets green light to make biologics at large Chinese plant →
← Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com